737001-07-9 Purity
98%
If you have any other questions or need other size, please get a quote.
Specification
Abdel-Hay, Mohamed H., et al. Microchemical Journal 147 (2019): 682-690.
Cyclopenthiazide (CYPZ) is a thiazide diuretic used in antihypertensive therapy. Its stability under forced degradation conditions (acidic, alkaline, neutral, oxidative, thermal, and photolytic stress) was evaluated using validated HPLC-DAD and HPTLC methods, and degradation kinetics were modeled via the Arrhenius equation to predict shelf life.
Experimental Protocol: CYPZ (alone or with amiloride) was subjected to 0.5 M HCl (acidic), 0.5 M NaOH (alkaline), water (neutral), 10% H2O2 (oxidative), dry heat (100 °C, 8 h), and UV/daylight exposure. Degradation was monitored by HPLC (C18 column, gradient methanol/phosphate buffer pH 3.0, 224 nm) and HPTLC (ethyl acetate:methanol:ammonia 8:2:0.2). Rate constants (k) were determined at 50-100 °C; Arrhenius plots (log k vs. 1/T) yielded activation energies (Ea) and extrapolated room-temperature half-lives (t1/2).
Performance Evaluation: CYPZ degraded fastest under acidic (t1/2 = 5.63 h at RT) and oxidative conditions (t1/2 = 30.13 h at RT), while neutral hydrolysis gave t1/2 = 13.72 h. UV irradiation caused 7.4% degradation after 8 h. Dry heat produced no degradation. Activation energies ranged from 8.16 kcal/mol (acidic) to 13.34 kcal/mol (oxidative). The HPLC method resolved CYPZ from all degradation products (retention time ~8.18 min), with peak purity confirmed by DAD.
Conclusion: Cyclopenthiazide is most labile under acidic and oxidative stress. The Arrhenius-based kinetic data enable prediction of its room-temperature stability, supporting formulation and storage recommendations.
Musini, Vijaya M., et al. Cochrane Database of Systematic Reviews 5 (2014).
Cyclopenthiazide is a thiazide diuretic used for hypertension. A systematic review of randomized, double-blind, placebo-controlled trials evaluated its dose-related blood pressure-lowering effect and metabolic impact.
Experimental Protocol: One trial (McVeigh 1988) randomized 53 patients (mean age 57 years, baseline BP 164/97 mmHg) to cyclopenthiazide 0.05, 0.125, or 0.5 mg/day or placebo for 8 weeks. Office blood pressure and serum biochemical parameters were measured. Risk of bias was assessed using Cochrane methods.
Performance Evaluation: The overall placebo-corrected systolic/diastolic blood pressure reduction was 10.8/6.2 mmHg (95% CI -18.4 to -3.1/-11.2 to -1.3). The lowest dose showing significant effect was 0.5 mg/day for systolic (-14.9 mmHg) and 0.125 mg/day for diastolic (-8.6 mmHg). Direct dose comparisons showed no dose-response relationship. Serum potassium decreased non-significantly (-0.18 mmol/L, 95% CI -0.42 to 0.07). Total cholesterol increased significantly by 0.79 mmol/L (95% CI 0.36 to 1.23). Uric acid and triglycerides showed non-significant increases. Withdrawals due to adverse effects were not reported. The trial had unclear risk of bias for most domains.
Conclusion: Cyclopenthiazide lowers blood pressure at low doses, with maximal effect likely achieved at 0.5 mg/day, but data are limited. Higher doses do not provide additional benefit but may increase metabolic adverse effects.
The molecular formula of cyclopenthiazide is C13H18ClN3O4S2.
Some synonyms of cyclopenthiazide include Cyclomethiazide, Benesal, and Navidrex.
The molecular weight of cyclopenthiazide is 379.9 g/mol.
The IUPAC name of cyclopenthiazide is 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide.
The InChIKey of cyclopenthiazide is BKYKPTRYDKTTJY-UHFFFAOYSA-N.
The CAS number of cyclopenthiazide is 742-20-1.
The UNII of cyclopenthiazide is VX4S2N85F5.
Yes, cyclopenthiazide is a thiazide diuretic.
Cyclopenthiazide has antihypertensive properties, meaning it can help lower blood pressure.
Cyclopenthiazide acts as a positive allosteric modulator at AMPA-A receptors.
Please kindly note that our products are for research use only.
Download